Search Results - "Espie, Pascal"

Immunosuppression Profile of CFZ533 (Iscalimab), a Non-Depleting Anti-CD40 Antibody, and the Presence of Opportunistic Infections in a Rhesus Monkey Toxicology Study by Flandre, Thierry D., Mansfield, Keith G., Espié, Pascal J., Rubic-Schneider, Tina, Ulrich, Peter

“…CFZ533 (iscalimab) is a nondepleting anti-CD40 antibody intended for inhibition of transplant organ rejection and treatment of autoimmune diseases. In a safety…”
Get full text

Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non‐depleting anti‐CD40 monoclonal antibody by Ristov, Jacinda, Espie, Pascal, Ulrich, Peter, Sickert, Denise, Flandre, Thierry, Dimitrova, Mirela, Müller‐Ristig, Dorothee, Weider, Doris, Robert, Gautier, Schmutz, Patrick, Greutmann, Barbara, Cordoba‐Castro, Francisco, Schneider, Martin A., Warncke, Max, Kolbinger, Frank, Cote, Serge, Heusser, Christoph, Bruns, Christian, Rush, James S.

“…The CD40‐CD154 costimulatory pathway is essential for T cell–dependent immune responses, development of humoral memory, and antigen presenting cell function…”
Get full text

Pharmacokinetics and Metabolism of 14C-Brivaracetam, a Novel SV2A Ligand, in Healthy Subjects by SARGENTINI-MAIER, Maria Laura, ESPIE, Pascal, COQUETTE, Alain, STOCKIS, Armel

“…This study was designed to investigate the human absorption, disposition, and mass balance of 14 C-brivaracetam, a novel high affinity SV2A ligand with potent…”
Get full text

First‐in‐human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti‐CD40 monoclonal antibody by Espié, Pascal, He, YanLing, Koo, Phillip, Sickert, Denise, Dupuy, Cyrielle, Chokoté, Edwige, Schuler, Roland, Mergentaler, Heidi, Ristov, Jacinda, Milojevic, Julie, Verles, Aurelie, Groenewegen, Andrea, Auger, Anita, Avrameas, Alexandre, Rotte, Michael, Colin, Laurence, Tomek, Charles S., Hernandez‐Illas, Martha, Rush, James S., Gergely, Peter

“…Iscalimab is a fully human, CD40 pathway blocking, nondepleting monoclonal antibody being developed as an immunosuppressive agent. We describe a…”
Get full text

Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study by GomezMancilla, Baltazar, Meriggioli, Matthew N, Genge, Angela, Roubenoff, Ronenn, Espié, Pascal, Dupuy, Cyrielle, Hartmann, Nicole, Pezous, Nicole, Kinhikar, Arvind, Tichy, Mia, Dionne, Annie, Vissing, John, Andersen, Henning, Schoser, Benedikt, Meisel, Andreas, Jordan, Berit, Devlikamova, Farida, Poverennova, Irina, Stuchevskaya, Fatima, Lin, Thy-Sheng, Rush, James S, Gergely, Peter

“…Increased morbidity in many patients with myasthenia gravis (MG) on long-term immunosuppression highlights the need for improved treatments. The aim of this…”
Get full text

Physiologically based pharmacokinetics (PBPK) by Espié, Pascal, Tytgat, Dominique, Sargentini-Maier, Maria-Laura, Poggesi, Italo, Watelet, Jean-Baptiste

“…Allometric scaling is widely used to predict human pharmacokinetic parameters from preclinical species, and many different approaches have been proposed over…”
Get full text

A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, for Control of Graves Hyperthyroidism-A Proof-of-Concept Trial by Kahaly, George J, Stan, Marius Nicolae, Frommer, Lara, Gergely, Peter, Colin, Laurence, Amer, Ahmed, Schuhmann, Imelda, Espie, Pascal, Rush, James S, Basson, Craig, He, Yanling

“…The CD40-CD154 co-stimulatory pathway plays an important role in the pathogenesis of Graves disease (GD) by promoting autoreactive B-cell activation. Evaluate…”
Get full text

PHASE 2 STUDY DESIGN EVALUATING EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF THE ANTI-CD40 MONOCLONAL ANTIBODY CFZ533 (ISCALIMAB) IN DE NOVO LIVER TRANSPLANT RECIPIENTS: THE CONTRAIL I STUDY by Nashan, Björn, Knechtle, Stuart J., Saliba, Faouzi, Laessing, Ute, Espie, Pascal, Klatt, Jan, Feng, Sandy

Get full text

A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, for Control of Graves Hyperthyroidism—A Proof-of-Concept Trial by Kahaly, George J, Stan, Marius Nicolae, Frommer, Lara, Gergely, Peter, Colin, Laurence, Amer, Ahmed, Schuhmann, Imelda, Espie, Pascal, Rush, James S, Basson, Craig, He, Yanling

“…Abstract Context The CD40-CD154 co-stimulatory pathway plays an important role in the pathogenesis of Graves disease (GD) by promoting autoreactive B-cell…”
Get full text

Gender and interindividual variability in pharmacokinetics by Nicolas, Jean-Marie, Espie, Pascal, Molimard, Mathieu

“…Like any other drugs, antiallergic medications can be associated with large inter- and intraindividual variability in their disposition. The best-documented…”
Get full text

Nonclinical Safety Assessment of CFZ533, a Fc-Silent Anti-CD40 Antibody, in Cynomolgus Monkeys by Ulrich, Peter, Flandre, Thierry, Espie, Pascal, Sickert, Denise, Rubic-Schneider, Tina, Shaw, David A, Rush, James S

“…Abstract CFZ533 is a pathway blocking, nondepleting anti-CD40 antibody that is in clinical development for inhibition of transplant organ rejection and therapy…”
Get full text

Novel Anti-CD40 Monoclonal Antibody CFZ533 in Patients with Primary Sjogren Syndrome: A Phase Iia Double-Blind, Placebo–Controlled Randomized Trial by Farag, Arwa, Papas, Athena, Fisher, Benjamin, Zeher, Margit, Ng, Wan-Fai, Bombardieri, Michele, Posch, Maximilian, Daikeler, Thomas, Bannert, Bettina, Kivitz, Alan, Carsons, Steven, Isenberg, David, Barone, Francesca, Bowman, Simon, Espie, Pascal, Wieczorek, Grazyna, Moulin, Pierre, Floch, David, Dupuy, Cyrielle, Ren, Xiaohui, Faerber, Petra, Wright, Andrew, Hockey, Hans Ulrich, Rotte, Michael, Rush, James, Gergely, Peter

Get full text

OR19-6 A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, Successfully Treats Graves’ Hyperthyroidism by Kahaly, George, Stan, Marius, Gergely, Peter, Colin, Laurence, Amer, Ahmed, Schuhmann, Imelda, Espie, Pascal, Rush, James, Basson, Craig, He, YanLing

“…Objective: Graves’ disease (GD) is an autoimmune disorder characterized by thyrotropin receptor autoantibody (TSHR-Ab)-mediated pathology, leading to…”
Get full text

Gender and interindividual variability in pharmacokinetics: Drug Metabolism and Disposition: Concepts and Applications in Allergic Diseases by NICOLAS, Jean-Marie, ESPIE, Pascal, MOLIMARD, Mathieu

Get full text

Pharmacokinetics and Metabolism of super(14)C-Brivaracetam, a Novel SV2A Ligand, in Healthy Subjects by Sargentini-Maier, Maria Laura, Espie, Pascal, Coquette, Alain, Stockis, Armel

“…This study was designed to investigate the human absorption, disposition, and mass balance of super(14)C-brivaracetam, a novel high affinity SV2A ligand with…”
Get full text

Physiologically based pharmacokinetics (PBPK): Drug Metabolism and Disposition: Concepts and Applications in Allergic Diseases by ESPIE, Pascal, TYTGAT, Dominique, SARGENTINI-MAIER, Maria-Laura, POGGESI, Italo, WATELET, Jean-Baptiste

Get full text

On isolated hepatocytes mitochondrial swelling induced in hypoosmotic medium does not affect the respiration rate by Espie, Pascal, Guerin, Bernard, Rigoulet, Michel

“…In isolated hepatocytes incubated in hypoosmotic media, a large increase in the mitochondrial volume is not directly involved in the activation of respiration…”
Get full text

Pharmacokinetics and Metabolism of 14 C-Brivaracetam, a Novel SV2A Ligand, in Healthy Subjects by Sargentini-Maier, Maria Laura, Espié, Pascal, Coquette, Alain, Stockis, Armel

Get full text

Energetics of swelling in isolated hepatocytes: a comprehensive study by Devin, A, Espié, P, Guérin, B, Rigoulet, M

“…Cell swelling is now admitted as being a new principle of metabolic control but little is known about the energetics of cell swelling. We have studied the…”
Get full text

Oxidative phosphorylation in intact hepatocytes: quantitative characterization of the mechanisms of change in efficiency and cellular consequences by Leverve, X, Sibille, B, Devin, A, Piquet, M A, Espié, P, Rigoulet, M

“…Two mechanisms may affect the yield of the oxidative phosphorylation pathway in isolated mitochondria: (i) a decrease in the intrinsic coupling of the proton…”
Get full text